Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias

NCT07342413 | Not Yet Recruiting Phase 4 FDA Drug

• 1 other identifier: Sclero-Epi-2025
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective is to compare physician-assessed clearance of telangiectatic veins between treatment legs using the Physician Global Aesthetic Improvement Scale (PGAIS). Secondary objectives include assessment of procedural pain, safety outcomes, and patient satisfaction.

Conditions

Leg Veins

Outcome Measures

Primary Outcomes (1)

• Physician Global Aesthetic Improvement Scale PGAIS

  Please rate right leg veins: Circle One * 2 Much Improved * 1 Improved 0 No Change * 1 Worse * 2 Much Worse Please rate left leg veins: Circle One * 2 Much Improved * 1 Improved 0 No Change * 1 Worse * 2 Much Worse

  Day 90

Secondary Outcomes (2)

• Patient Satisfaction Likert Score for vein improvement

  Day 90

• Visual Analog Pain Scale Post Treatment

  Day 1 and Day 30

Study Arms (2)

Group A Right Leg Treated with glycerin compounded 1% lidocaine and epinephrine

ACTIVE COMPARATOR

Subjects will be treated with foamed sodium tetradecyl sulfate (STS) to both legs. Four weeks later subjects left leg will be treated with glycerin compounded with 1% lidocaine, and right leg will be treated with glycerin compounded with 1% lidocaine and epinephrine.

Drug: Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine

Group B Left Leg Treated with glycerin compounded 1% lidocaine and epinephrine

SHAM COMPARATOR

Subjects will be treated with foamed sodium tetradecyl sulfate (STS) to both legs. Four weeks later subjects right leg will be treated with glycerin compounded with 1% lidocaine, and left leg will be treated with glycerin compounded with 1% lidocaine and epinephrine.

Drug: Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine

Interventions

Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine DRUG

Left leg treated with glycerin compounded with 1% lidocaine and epinephrine

Group B Left Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine DRUG

Right leg treated with glycerin compounded with 1% lidocaine and epinephrine

Group A Right Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects aged 20-75years.
• Fitzpatrick skin types I-VI.
• Presence of lower extremity telangiectatic veins (\<1 mm) suitable for sclerotherapy (reticular veins ≥1 mm can be present but are not required).
• Duplex ultrasonography negative for saphenous vein reflux in both legs.
• Willing to undergo split-leg randomization (CG + 1% lidocaine vs CG + 1% lidocaine with epinephrine 1:100,000).
• Willing and able to comply with all study procedures, including standardized photography, in-person evaluations by a non-treating physician investigator, Day 90 follow-up assessments, and post-treatment compression therapy consisting of graduated 30-40 mmHg stockings worn 24 hours/day for 1 week following treatment.
• Subject with no known history of coagulopathy/platelet disorders (eg., hemophilia, von Willebrand disease) or liver disease/cirrhosis
• Subject with no history of hypercoagulable disorder such as pulmonary embolism, deep vein thrombosis, factor V Leiden mutation, Protein C or S deficiency, antiphospholipid syndrome, or active malignancy
• Subjects in good general health as determined by the investigator's judgment and medical history.
• Participants must be willing to provide written informed consent and sign a photography release for research and potential publication. Subjects must also agree to complete all study visits and procedures.
• Willing to avoid new lower-extremity aesthetic/vascular treatments (e.g., sclerotherapy, vascular lasers) and agree to avoid self-tanners or spray tans on the legs during the study period.
• Negative urine pregnancy test result at the time of study entry and all subsequent visits (if applicable)
• Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.
• Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device/coil, bilateral tubal ligation, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and/or vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.
• A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months/≥ 12 months of amenorrhea without another medical cause), without a uterus (hysterectomy) and/or both ovaries (oophorectomy).

You may not qualify if:

• Positive duplex ultrasonography demonstrating saphenous vein reflux.
• Prior sclerotherapy or vascular laser treatment to the lower extremities within the past 6 months prior to screening/baseline
• History of ulceration, thrombophlebitis, or deep vein thrombosis (DVT) in the lower extremities.
• Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.
• Known allergy or hypersensitivity to lidocaine, epinephrine, or glycerin.
• Any uncontrolled systemic condition that may increase risk or interfere with study participation (e.g., poorly managed diabetes, thyroid dysfunction, cardiovascular disease).
• Pregnancy, intent to become pregnant during the study period, or current breastfeeding.
• Clinically significant psychiatric or psychological conditions that, in the opinion of the investigator, may interfere with compliance or interpretation of results
• Participation in another clinical study within 30 days prior to enrollment of this study or during this study.
• Unwillingness to refrain from additional lower extremity aesthetic/vascular treatments (e.g., sclerotherapy, vascular lasers, self-tanning) from the screening/baseline visit through the end of study.
• Unwillingness to follow a wash-out period of 4 weeks prior to screening for self-tanner application.
• Unwillingness to refrain from self-tanner application for 1 month prior to any visits.
• Unwillingness or inability to comply with post-treatment compression therapy consisting of graduated 30-40 mmHg stockings worn 24 hours/day for 1 week following treatment

Sponsors & Collaborators

• Goldman, Butterwick, Fitzpatrick and Groff: lead

Study Sites (1)

West Dermatology Research Center

San Diego, California, 92121, United States

Location

MeSH Terms

Interventions

Lidocaine; Epinephrine

Intervention Hierarchy (Ancestors)

Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines; Ethanolamines; Amino Alcohols; Alcohols; Biogenic Monoamines; Biogenic Amines; Catecholamines; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons

Central Study Contacts

Andrea Pacheco

CONTACT

858-657-1004; apacheco@clderm.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2026
• First Posted: January 15, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): May 30, 2026
• Study Completion (Estimated): July 30, 2026
• Last Updated: January 15, 2026

Record last verified: 2026-01

Locations

US (1)